Corvus reports Q4 net loss of $9.2M, cash $69.5M; plans Phase 2 trials in NSCLC and RCC

Corvus Pharmaceuticals, Inc.

Net loss Q4 2021 $9.2M vs net income $27.3M in Q4 2020 (incl $37.5M deconsolidation gain).
Full year 2021 net loss $43.2M vs $6.0M in 2020; R&D expenses $29.1M down from $31.8M.
Cash, equivalents and securities $69.5M at Dec 31, 2021, up from $44.3M; FY2022 cash burn guidance $34-36M.
Plans randomized Phase 2 trial of mupadolimab plus chemo in front-line NSCLC (150 patients).
Plans Phase 2 trial of ciforadenant plus ipilimumab/nivolumab in front-line RCC with Kidney Cancer Consortium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.